, 102mr3 (2011);
3 Sci Transl Med
, et al. Martien J. Kas
Between Mouse and Man
Translational Neuroscience of Schizophrenia: Seeking a Meeting of Minds
for schizophrenia; a summary and the conclusions are presented.
A meeting held 9 June 2011 in Helsinki, Finland, discussed the requirements for creating useful mouse models
can be found at:
and other services, including high-resolution figures,
A complete electronic version of this article
in whole or in part can be found at:
permission to reproduce this
of this article or about obtaining
Information about obtaining
is a registered trademark of AAAS. Science Translational Medicinerights reserved. The title
NW, Washington, DC 20005. Copyright 2011 by the American Association for the Advancement of Science; all
last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue
(print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except theScience Translational Medicine
on September 28, 2011
Translational Neuroscience of Schizophrenia:
Seeking a Meeting of Minds Between Mouse and Man
Martien J. Kas,1* René S. Kahn,2David A. Collier,3John L. Waddington,4Jesper Ekelund,5
David J. Porteous,6Klaus Schughart,7Iiris Hovatta8,9
Understanding the etiology of developmental brain disorders such as schizophrenia is critical for achieving
advances in treatment and requires new research strategies that control for individual variation in genetic
background, environmental challenges, and expression of phenotype. SYSGENET, a European systems genetics
network for the study of complex genetic human diseases with mouse genetic reference populations, brought
together in Helsinki a cross-disciplinary group of clinical and basic scientists and mouse geneticists to debate,
formulate, and prioritize a strategy for future research based on mouse models. The main conclusions of this
meeting are summarized here.
Schizophrenia is a psychotic disorder characterized by positive and neg-
ative symptoms, including reality distortion (delusions and halluci-
nations), psychomotor poverty (poverty of speech, social withdrawal,
and blunting of affect), and disorganization (inappropriate affect and
thought disorder), together with cognitive deficits; negative symptoms
and cognitive deficits are the primary determinants of poor functional
outcome. Lifetime risk for schizophrenia is about 1%, and because of
its onset in early adulthood and severity, it causes considerable disabil-
ity to patients and high socioeconomic costs to society. Schizophrenia
is a complex disease influenced by both genetic and environmental fac-
tors, with heritability estimated at about 80%. In recent years, several
susceptibility genes have been identified in human cohorts, leading to
new insights into pathogenetic mechanisms of this neurodevelopmen-
tal disorder (1–3). However, current medications for schizophrenia are
only partially effective; for example, although they reduce psychotic
symptoms, current drugs are minimally effective in improving cogni-
tion (4) and induce a range of potentially life-threatening long-term
side effects. Therefore, there is a need for better treatment practices
for schizophrenia that target positive and negative symptoms and im-
prove cognitive deficits. Increased understanding of the neurobiological
mechanisms underlying schizophrenia should facilitate this task.
Merging knowledge from genetics, genomics, epidemiology, phys-
iology, and pharmacology, including both preclinical and clinical
studies, is needed to resolve core aspects of schizophrenia. In this
regard, studies using animal models can contribute considerably to
a better understanding of the biological processes that underlie dis-
ease risk and development. Experimental animal models will also be
required for the development of new, etiology-directed medication.
The mouse is well placed to address most of these requirements, by
virtue of its advanced genetics, understanding of developmental and
behavioral biology, short generation time, and low cost (5). In par-
ticular, the effects of targeted, experimental, and natural genetic var-
iations and their phenotypic consequences can be studied in mouse
populations or in genetically engineered lines, such as mouse gene
knockout lines (6, 7). However, to provide real insight and to be of
meaningful translational value, it is first essential to identify the core
biological phenotypes and mechanisms that underpin schizophrenia.
This challenge was the focus of the targeted workshop of SYSGENET
on cross-species studies of schizophrenia.
CORE FEATURES OF SCHIZOPHRENIA
Compromised function of the nervous system in schizophrenia is ev-
ident, on a population basis, as early as the first year of life when pa-
tients show slightly delayed developmental milestones such as walking
(8). Manifestations become more evident during early adolescence
(ages 11 to 16 years) and are characterized by cognitive decline and
social withdrawal. During late adolescence/young adulthood (16 to
25 years), the first symptoms of psychosis appear, most typically hal-
lucinations and delusions. Thus, the first material signs of the illness
are not the more obvious psychotic symptoms but, rather, the slow
but steady decline in cognitive functioning that precedes the onset of
psychosis by an average of 9 years (9, 10) and may continue to pro-
gress thereafter (11). Indeed, cognitive dysfunction constitutes not
only one of the core features of the illness (10) but also one of the
most intractable to treat (4). Although the words “dementia praecox,”
as Kraepelin named the disease he delineated in 1895, may not carry
a hopeful message, the “dementia,” that is, the cognitive decline, re-
flects a core process in the illness we currently call schizophrenia.
Not only does cognition worsen during the early course of schizo-
phrenia, there is accompanying loss of cerebral gray matter in excess
of what is seen with normal aging. Brain imaging studies in healthy
humans have revealed that the developing and aging human brain
1Department of Neuroscience and Pharmacology, University Medical Center Utrecht,
3584CG Utrecht, Netherlands.2Department of Psychiatry, Rudolf Magnus Institute of
Neuroscience, University Medical Center Utrecht, 3584CX Utrecht, Netherlands.3Social
Genetic and Developmental Psychiatry Centre, Kings College London, Institute of
Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.4Molecular and
Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland.5Depart-
ment of Psychiatry, University of Helsinki, Vaasa Hospital District and Mental Health
and Substance Abuse Services, National Institute of Health and Welfare, 00251 Helsinki,
Finland.6Medical Genetics Section, University of Edinburgh Centre for Molecular Medicine,
Institute of Genetics and Molecular Medicine, Western General Hospital, Crewe Road,
Edinburgh EH4 2XU, UK.7Department of Infection Genetics, Helmholtz Centre for In-
fection Research and University of Veterinary Medicine Hannover, 38124 Braunschweig,
Germany.8Research Programs Unit, Molecular Neurology, Biomedicum-Helsinki and
Haartman Institute, Department of Medical Genetics, University of Helsinki, 00290 Helsinki,
Finland.9Mental Health and Substance Abuse Services, National Institute for Health and
Welfare, 00300 Helsinki, Finland.
*To whom correspondence should be addressed. E-mail: firstname.lastname@example.org
www.ScienceTranslationalMedicine.org 28 September 2011Vol 3 Issue 102 102mr3
on September 28, 2011
undergoes dynamic changes in volume over time. Specifically, abso-
lute brain volume increases up to early puberty and, thereafter, de-
clines before the age of 20 (11). Then, there is a short episode with
slight growth followed by a decline, until a stable brain volume is
achieved around the ages of 25 to 40 years. In contrast, at illness onset,
brain volume in schizophrenic patients is already reduced relative to
matched healthy controls; subsequently, such patients exhibit an ac-
celerated decrease in brain volume, especially in frontal and temporal
cortical brain areas (11). This progressive reduction in cortical volume
in schizophrenia can occur independent of medication (12), is herita-
ble (13), and is correlated with poor prognosis and psychosis severity
(14). Cannabis use, the strongest known environmental risk factor for
schizophrenia identified thus far, worsens gray matter brain volume
loss in schizophrenia (15, 16).
A recent study aimed to reduce phenotypic heterogeneity in a large
sample of psychosis patients, their relatives, and community controls
by using latent class analysis to analyze variation in Comprehensive
Assessment of Symptoms and History (CASH) lifetime-rated symp-
toms (17). This study revealed that variation in five continuous di-
mensions (disorganization, positive, negative, mania, and depression)
was accounted for by the presence of seven homogeneous classes
(Kraepelinian schizophrenia, affective psychosis, manic depression,
deficit nonpsychosis, depression, healthy, and no symptoms). This
analysis showed that almost all (85%) of these schizophrenic patients
were assigned to the Kraepelinian schizophrenia class, whereas the
remaining patients were assigned to the affective psychosis class. Analy-
ses of symptom variation revealed that the difference between schizo-
phrenia and affective psychosis within the patient sample is based on
the distinction between low and high levels of disorganization and
negative symptoms, rather than on the level of positive, psychotic
symptoms. Levels of disorganization and negative symptoms are also
associated with diminished cognitive performance and poor outcome,
suggesting that these may be relevant dimensions to model in mice.
Together, these findings indicate that schizophrenia is a complex
neurodevelopmental disease of cognitive decline associated with pro-
gressive brain loss, negative symptoms, and the emergence of psychotic
symptoms that lead to diagnosis. The presence of measurable physio-
logical parameters should make it possible to study well-defined pheno-
types in mouse populations and mutants and to determine the genetic
basis for premature, disease-related brain loss.
HUMAN GENETIC FINDINGS
Although the heritability of schizophrenia is high, at about 80% (18), it
has been challenging to identify predisposing variants for schizo-
phrenia in humans. Early studies using linkage mapping, cytogenetic
analysis, and candidate gene studies identified several putative suscep-
tibility genes, including the dopamine receptor 2 (DRD2), neuregulin 1
(NRG1) (19), dysbindin (DTNBP1) (20), and disrupted in schizo-
phrenia 1 (DISC1) (21).The recent common variant–common disease
hypothesis has stimulated a number of genome-wide association studies
(GWAS) and resulted in the identification of variants with weaker
effects, including ZNF804A (22). Several international consortia, in-
cluding SGENE, the ISC (International Schizophrenia Consortium),
and the MGS (Molecular Genetics of Schizophrenia Collaboration),
detected their strongest association signals in the major histocom-
patibility complex (MHC) region, which seem to come from two par-
tially independent signals: one in the large histone gene cluster on
chromosome 6, near the MHC class I region, and another one near
the NOTCH4 gene, which also tags classical human leukocyte antigen
(HLA) alleles DRB1 and HLA-B (23–25). They also identified other
loci, including TCF4 and Neurogranin (23). Follow-up analyses, includ-
ing studies by the Psychiatric Genetics Consortium, and other groups
(26, 27) are gradually identifying further GWAS-significant loci.
Several rare, de novo copy number variants (CNVs) have also been
recently associated with schizophrenia, including deletions at 15q13.3,
1q21.1, neurexin (28), and 17p12 (29) and duplications at 16p11.2,
16p13.1 (30, 31), and VIPR2 (32–34). CNVs at some of these loci as-
sociate also with other phenotypes, including bipolar disorder, autism
spectrum disorders [for example, (29)], cardiovascular diseases such as
aortic dissection and teratology of Fallot (35), and obesity (36); these
findings have important implications with regard to potential DNA
diagnostics, understanding disease etiology across disorders, and treat-
ment development. Even though important disease pathways are be-
ginning to emerge, more than 90% of the heritability of schizophrenia
remains to be explained and larger samples and sequencing-based
approaches are expected to shed light on this issue. It is interesting
that the occurrence of de novo CNVs and recent rare point mutations
may explain why psychiatric diseases with a reduced fecundity, such
as schizophrenia and autism, remain common in the human popula-
GENETIC MOUSE MODELS
The contribution, not only of common risk variants but also of deleted
or duplicated de novo CNV regions in schizophrenia, suggests that
transgenic animals, such as knockouts or knock-ins for these specific
gene regions, may allow determination of genetic causality for schizo-
phrenia. Most mutants studied thus far do not model schizophrenia
per se; rather, they assess the functional roles of genes associated with
risk for schizophrenia (for example, DISC1, DTNBP1, and NRG1) or
putative endophenotypes (for example, Comt deletion in relation to
cognitive phenotypes). Furthermore, studying the “mental health” of
mice is challenging. There may be an unappreciated role for etholog-
ical, species-specific behaviors that become apparent in more natural-
istic settings, including components of the mouse ethogram such as
nest building. Current approaches (38, 39) have more commonly in-
volved trans-species models of positive symptoms (for example, pre-
pulse inhibition), negative symptoms (for example, social behavior),
and cognitive dysfunction (for example, working memory). In the case
of N-ethyl-N-nitrosourea–induced, amino acid substitution Disc1
mouse models, the behavioral phenotypes and pharmacological rescue
are allele-dependent (40). Certain features of schizophrenia, such as
poverty of speech, may be uniquely human. However, anhedonia,
asociality, and avolition are at least theoretically accessible in both hu-
mans and animals and can be studied in relation to genetic risk factors
for schizophrenia (41). For example, Nrg1 mutant mice have selective
disruption of the normal preference for social novelty (42). However,
the uncertainty regarding the clinical concept of schizophrenia means
that the predictive validity for such mutant phenotypes and their
pathobiology is similarly uncertain. Studies with cross-sectional mag-
netic resonance imaging have shown that, in contrast to patients with
schizophrenia, Nrg1 mutant mice have slightly smaller total ventricu-
lar volume and cerebellum when compared to wild-type controls (43).
www.ScienceTranslationalMedicine.org 28 September 2011 Vol 3 Issue 102 102mr3
on September 28, 2011
Gene × environment (G × E) interactions are evident in mice; for
example, interactions (i) between maternal immune activation and
Nrg1 mutation, (ii) between adolescent social defeat and Nrg1 muta-
tion, and (iii) between adolescent cannabis exposure and Comt mu-
tation regulate subsequent mouse phenotypes such as social behavior
and working memory in young adulthood (44). Such studies suggest
that, in patients, the overall psychosis phenotype may be influenced by
the interaction of risk genes with both biological and psychosocial
environmental adversities operating at critical time points during de-
velopment, but the applicability of these results from mice to patients
is still uncertain.
Genetic information has the potential to aid clinicians in risk predic-
tion and diagnostics. Both of these approaches are routinely carried
out for monogenic diseases. Certain rare genomic lesions have high
predictive value for schizophrenia, such as the t(1;11) disruption of
DISC1 (45), or the velocardiofacial syndrome (VCSF) deletion locus
on chromosome 22q11 (46). Unfortunately, GWAS of schizophrenia
published to date have generated low values for the relative risk
provided by the identified risk alleles. For example, the International
Schizophrenia Consortium (ISC) reported odds ratios of around 1.2
for their most important findings, with the risk-conferring allele being
very prevalent, around 80 to 90% in most cases (25). Translated into a
predictive test, this has very low specificity and no clinical utility. Com-
bining genetic risk factors to create a genetic risk score has been at-
tempted for other complex phenotypes, leading both to negative results
for height (47) and cardiovascular traits (48) and to statistically signif-
icant but not clinically applicable for type 2 diabetes (49) and coronary
heart disease (50). The current genetic findings do not allow clinically
relevant tests to be performed, but such tests may be possible when the
genetic landscape of schizophrenia becomes better characterized.
Nevertheless, clinical studies in schizophrenia can inform selection
of the most relevant phenotypes for studies in mice. When construct-
ing a mouse to model aspects of schizophrenia, it is important to dis-
tinguish whether one seeks to model a rare, severe trait, potentially
with quantitative endophenotypes, or a trait that is present quantita-
tively in the human population. Traditionally, a stress-diathesis model
has prevailed. This model views disease state as dichotomous but the
underlying risk phenotypes as quantitative. There is also evidence to
suggest that the actual phenotype of psychosis is common and quan-
titatively distributed in the population, with no point of rarity. First,
more than 3% of individuals have a diagnosed psychotic disorder (51).
Moreover, brief auditory illusions when falling asleep/waking up are
common and normal; many widowed persons have sensory impres-
sions of their loved ones; experimental sleep deprivation and sensory
deprivation can cause hallucinations in experimental settings. When
susceptibility to psychosis in the population is assessed by a question-
naire (the Perceptual Aberration Scale), less than half of individuals
report no psychotic-like experiences and the number of psychotic-like
experiences in the population follows a Poisson distribution, with no
point of rarity (52). These findings do not support a dichotomous view
of psychosis in itself. The research community seems divided on this
dichotomous/continuous debate, and whichever eventually turns out
to be true, it is something to keep in mind when constructing mouse
models for this disorder.
Another important issue to consider is which human phenotypes
can be modeled in the mouse and which are human-specific (53). Re-
cent cognitive neuropsychiatric models of psychosis emphasize the
role of attention disturbances and inappropriate incentive learning
in the development of disturbances of thought, such as delusions. It
is clear that more proximal phenotypes, such as sensory gating ab-
normalities, would be a better choice for modeling in mouse than
human-specific, distal phenotypes like delusions of reference. The
most critical question is where on this proximal-distal scale to put
traits such as disruption to social behavior and brain imaging abnor-
malities. These considerations suggest that the phenotypes to be
modeled in the mouse should be a reliably detectable, physiological
measure of proximal processes in the etiological chain of events in
MODELING CLINICAL RELEVANT PHENOTYPES IN MICE
This overview of our current knowledge of the neurobiology of schizo-
phrenia signals an urgent need for animal models that also take into
account the genetic complexity of the small effect size genetic variants
that contribute to the development of core features of the disease. One
main conclusion from this workshop was that schizophrenia is a com-
plex neurodevelopmental disease associated with early, progressive
cognitive decline in association with accelerated reduction in brain
volume of cortical areas and, possibly, the cerebellum. Manifestation
of the diagnostic symptoms of psychosis during late adolescence may
result from the effects of moderate- to high-risk mutations such as
CNVs in some individuals and interaction of a large number of low-
risk polymorphisms with several environmental adversities at critical
time points during development. Future studies should aim at devel-
oping specific, standardized phenotypes to be measured longitudinally,
including cortical thickness and other structural phenotypes, cognitive
phenotypes, prepulse inhibition, sociability/social novelty prefer-
ence, and habituation of exploratory behavior in a novel environment.
These phenotypes will need to be assessed in standardized contexts of
G × G and G × E interaction and measured longitudinally to address
both multifactorial and progressive aspects such as reduction in brain
volume and cognitive decline. Here, mouse model systems will be of
MOUSE MODELS CAN INFORM STUDY OF THE ETIOLOGY
Targeted therapies for schizophrenia are desperately needed, but their
development and effective use require understanding the molecular
mechanisms involved in the etiology of schizophrenia. Genetics offer
an ideal route to the molecular basis of schizophrenia, as any identified
genes can potentially be linked to their functions from the cellular to
the behavioral level. Mouse models can be very informative both in
the identification of susceptibility genes and in understanding their
biological function (5, 38). In addition to revealing the function of
the gene in a defined genetic background (39), single gene knockout
mouse models of candidate genes for schizophrenia allow studies of
G × E interactions (44). Furthermore, the same mice can be used in
detailed analysis of gene expression, proteomic, and neuronal phe-
notypes both in the intact brain and in cellular models to provide
www.ScienceTranslationalMedicine.org 28 September 2011Vol 3 Issue 102 102mr3
on September 28, 2011
additional tools for drug development and testing (for example, with
approaches such as connectivity mapping) (54). Some of these models,
such as those that exhibit positive symptoms, can be validated with
existing drugs for schizophrenia to provide some predictive validity
(40). However, others, such as those with negative symptoms and cog-
nitive dysfunction, which respond poorly even to clozapine, cannot be
validated in this way (53).
On the other hand, clinically relevant mouse models of schizo-
phrenia will complement human genetic efforts to identify small effect
susceptibility variants, because human GWAS fail to capture more
than a modest fraction of the measured heritability (55). Quantitative
trait locus (QTL) mapping with mice has been used to identify sus-
ceptibility genes for endophenotypes of schizophrenia, including ven-
tricular size (56) and prepulse inhibition (57–60) in F2animals and
chromosome substitution strains. However, the relatively small num-
ber of highly polymorphic alleles in these strains might not be optimal
in identifying genes for complex diseases such as schizophrenia.
At the core of the SYSGENET network (http://www.helmholtz-hzi.
de/sysgenet/) is the use of mouse genetic reference populations (GRPs).
An important new GRP that will soon become available is the Collab-
orative Cross (CC), comprising a large panel of recombinant inbred
(RI) strains derived from a genetically diverse set of eight founder
strains and designed specifically for complex trait analysis (61, 62).
The CC population also includes wild derived mouse strains and thus
represents a greater degree of genetic variation than do currently avail-
able GRPs. This resource should offer larger phenotypic and behavioral
variations that are relevant to schizophrenia and other neurodevelop-
mental and behavioral disorders. GRPs also have the intrinsic advan-
tages of access to brain tissue at any chosen developmental time point,
before or after behavioral testing and/or environmental or pharmaco-
logical intervention. Polymorphisms within susceptibility genes may
lead to differences in gene function or expression; these differences
can be studied with gene expression, proteomic, and metabolomic
analyses, allowing identification of gene regulatory networks perturbed
in schizophrenia. Therefore, the set of clinically relevant phenotypes
discussed above should be measured in the CC population. Longitu-
dinal quantitative measurements of brain morphology (for example,
cortical thickness), sensory processing, and behavioral phenotypes
(for example, social behavior) in GRPs will allow the systematic
modeling of clinically relevant phenotypes of schizophrenia at differ-
ent developmental stages and under controlled genetic and environ-
mental conditions (Table 1).
All participants of the meeting concluded that there is a real oppor-
tunity and need for knowledge exchange between preclinical and clin-
ical researchers to better understand the etiology of schizophrenia and
related developmental brain disorders. The laboratory mouse can play
a vital role in constructing and testing hypotheses of direct transla-
tional relevance. The CC will provide an important complement to
the established armamentariumofmouse genetic techniquesand tools.
REFERENCES AND NOTES
1. A. Buonanno, The neuregulin signaling pathway and schizophrenia: From genes to
synapses and neural circuits. Brain Res. Bull. 83, 122–131 (2010).
2. M. Johnstone, P. A. Thomson, J. Hall, A. M. McIntosh, S. M. Lawrie, D. J. Porteous, DISC1 in
schizophrenia: Genetic mouse models and human genomic imaging. Schizophr. Bull. 37,
3. M. Kvajo, H. McKellar, J. A. Gogos, Molecules, signaling, and schizophrenia. Curr. Top.
Behav. Neurosci. 4, 629–656 (2010).
4. M. Davidson, S. Galderisi, M. Weiser, N. Werbeloff, W. W. Fleischhacker, R. S. Keefe, H. Boter,
I. P. Keet, D. Prelipceanu, J. K. Rybakowski, J. Libiger, M. Hummer, S. Dollfus, J. J. López-Ibor,
L. G. Hranov, W. Gaebel, J. Peuskens, N. Lindefors, A. Riecher-Rössler, R. S. Kahn, Cognitive
effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform
disorder: A randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166, 675–682
5. M. J. Kas, V. Krishnan, T. D. Gould, D. A. Collier, B. Olivier, K. P. Lesch, E. Domenici, E. Fuchs,
C. Gross, E. Castrén, Advances in multidisciplinary and cross-species approaches to examine
the neurobiology of psychiatric disorders. Eur. Neuropsychopharmacol. 21, 532–544 (2011).
6. M. J. Kas, C. Gelegen, L. C. Schalkwyk, D. A. Collier, Interspecies comparisons of func-
tional genetic variations and their implications in neuropsychiatry. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 150B, 309–317 (2009).
7. M. J. Kas, C. Fernandes, L. C. Schalkwyk, D. A. Collier, Genetics of behavioural domains
across the neuropsychiatric spectrum; of mice and men. Mol. Psychiatry 12, 324–330 (2007).
8. J. van Os, S. Kapur, Schizophrenia. Lancet 374, 635–645 (2009).
9. C. J. van Oel, M. M. Sitskoorn, M. P. Cremer, R. S. Kahn, School performance as a premorbid
marker for schizophrenia: A twin study. Schizophr. Bull. 28, 401–414 (2002).
10. A. Reichenberg, A. Caspi, H. Harrington, R. Houts, R. S. Keefe, R. M. Murray, R. Poulton,
T. E. Moffitt, Static and dynamic cognitive deficits in childhood preceding adult
schizophrenia: A 30-year study. Am. J. Psychiatry 167, 160–169 (2010).
11. A. M. Hedman, N. E. van Haren, H. G. Schnack, R. S. Kahn, H. E. Hulshoff Pol, Human brain
changes across the life span: A review of 56 longitudinal magnetic resonance imaging
studies. Hum. Brain Mapp. 10.1002/hbm.21334 (2011).
12. T. B. Ziermans, P. F. Schothorst, H. G. Schnack, P. C. Koolschijn, R. S. Kahn, H. van Engeland,
S. Durston, Progressive structural brain changes during development of psychosis.
Schizophr. Bull. 10.1093/schbul/sbq113 (2010).
13. R. G. Brans, N. E. van Haren, G. C. van Baal, H. G. Schnack, R. S. Kahn, H. E. Hulshoff Pol,
Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia.
Arch. Gen. Psychiatry 65, 1259–1268 (2008).
14. H. E. Hulshoff Pol, R. S. Kahn, What happens after the first episode? A review of progressive
brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 34, 354–366
15. M. Rais, N. E. van Haren, W. Cahn, H. G. Schnack, C. Lepage, L. Collins, A. C. Evans,
H. E. Hulshoff Pol, R. S. Kahn, Cannabis use and progressive cortical thickness loss in areas
rich in CB1 receptors during the first five years of schizophrenia. Eur. Neuropsychopharmacol.
20, 855–865 (2010).
16. M. Rais, W. Cahn, N. Van Haren, H. Schnack, E. Caspers, H. Hulshoff Pol, R. Kahn, Excessive
brain volume loss over time in cannabis-using first-episode schizophrenia patients.
Am. J. Psychiatry 165, 490–496 (2008).
17. E. M. Derks, J. Allardyce, M. P. Boks, J. K. Vermunt, R. Hijman, R. A. Ophoff; GROUP, Kraepelin
was right: A latent class analysis of symptom dimensions in patients and controls.
Schizophr. Bull. 10.1093/schbul/sbq103 (2010).
Table 1. Core features of schizophrenia for mouse modeling.
Critical developmental stages Age-matched developmental stages
Disease progressionLongitudinal phenotypic assessment
Environmental factorsMaternal infection/stressful
Candidate genes Targeted and “humanized” genetic models
Genetic background/epistasis Collaborative cross/crossing mutant lines
Phenotypes Cognitive decline
Sensory processing (for example,
www.ScienceTranslationalMedicine.org 28 September 2011Vol 3 Issue 102 102mr3
on September 28, 2011
18. A. G. Cardno, I. I. Gottesman, Twin studies of schizophrenia: From bow-and-arrow concor-
dances to Star Wars Mx and functional genomics. Am. J. Med. Genet. 97, 12–17 (2000).
19. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir, S. Bjornsdottir, T. Sigmundsson, S. Ghosh,
J. Brynjolfsson, S. Gunnarsdottir, O. Ivarsson, T. T. Chou, O. Hjaltason, B. Birgisdottir,
H. Jonsson, V. G. Gudnadottir, E. Gudmundsdottir, A. Bjornsson, B. Ingvarsson, A. Ingason,
S. Sigfusson, H. Hardardottir, R. P. Harvey, D. Lai, M. Zhou, D. Brunner, V. Mutel, A. Gonzalo,
G. Lemke, J. Sainz, G. Johannesson, T. Andresson, D. Gudbjartsson, A. Manolescu, M. L. Frigge,
M. E. Gurney, A. Kong, J.R. Gulcher, H. Petursson, K. Stefansson, Neuregulin 1 and susceptibility
to schizophrenia. Am. J. Hum. Genet. 71, 877–892 (2002).
20. R. E. Straub, Y. Jiang, C. J. MacLean, Y. Ma, B. T. Webb, M. V. Myakishev, C. Harris-Kerr,
B. Wormley, H. Sadek, B. Kadambi, A. J. Cesare, A. Gibberman, X. Wang, F. A. O’Neill,
D. Walsh, K. S. Kendler, Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog
of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71,
21. J. K. Millar, J. C. Wilson-Annan, S. Anderson, S. Christie, M. S. Taylor, C. A. Semple,
R. S. Devon, D. M. St Clair, W. J. Muir, D. H. Blackwood, D. J. Porteous, Disruption of two
novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9,
22. M. C. O’Donovan, N. Craddock, N. Norton, H. Williams, T. Peirce, V. Moskvina, I. Nikolov,
M. Hamshere, L. Carroll, L. Georgieva, S. Dwyer, P. Holmans, J. L. Marchini, C. C. Spencer,
B. Howie, H. T. Leung, A. M. Hartmann, H. J. Möller, D. W. Morris, Y. Shi, G. Feng,
P. Hoffmann, P. Propping, C. Vasilescu, W. Maier, M. Rietschel, S. Zammit, J. Schumacher,
E. M. Quinn, T. G. Schulze, N. M. Williams, I. Giegling, N. Iwata, M. Ikeda, A. Darvasi,
S. Shifman, L. He, J. Duan, A. R. Sanders, D. F. Levinson, P. V. Gejman, S. Cichon,
M. M. Nöthen, M. Gill, A. Corvin, D. Rujescu, G. Kirov, M. J. Owen, N. G. Buccola,
B. J. Mowry, R. Freedman, F. Amin, D. W. Black, J. M. Silverman, W. F. Byerley,
C. R. Cloninger; Molecular Genetics of Schizophrenia Collaboration, Identification of
loci associated with schizophrenia by genome-wide association and follow-up.
Nat. Genet. 40, 1053–1055 (2008).
23. H. Stefansson, R. A. Ophoff, S. Steinberg, O. A. Andreassen, S. Cichon, D. Rujescu, T. Werge,
O. P. Pietiläinen, O. Mors, P. B. Mortensen, E. Sigurdsson, O. Gustafsson, M. Nyegaard,
A. Tuulio-Henriksson, A. Ingason, T. Hansen, J. Suvisaari, J. Lonnqvist, T. Paunio, A. D. Børglum,
A. Hartmann, A. Fink-Jensen, M. Nordentoft, D. Hougaard, B. Norgaard-Pedersen, Y. Böttcher,
J. Olesen, R. Breuer, H. J. Möller, I. Giegling, H. B. Rasmussen, S. Timm, M. Mattheisen, I. Bitter,
J. M. Réthelyi, B. B. Magnusdottir, T. Sigmundsson, P. Olason, G. Masson, J. R. Gulcher,
M. Haraldsson, R. Fossdal, T. E. Thorgeirsson, U. Thorsteinsdottir, M. Ruggeri, S. Tosato,
B. Franke, E. Strengman, L. A. Kiemeney; Genetic Risk and Outcome in Psychosis
(GROUP), I. Melle, S. Djurovic, L. Abramova, V. Kaleda, J. Sanjuan, R. de Frutos, E. Bramon,
E. Vassos, G. Fraser, U. Ettinger, M. Picchioni, N. Walker, T. Toulopoulou, A. C. Need, D. Ge,
J. L. Yoon, K. V. Shianna, N. B. Freimer, R. M. Cantor, R. Murray, A. Kong, V. Golimbet,
A. Carracedo, C. Arango, J. Costas, E. G. Jönsson, L. Terenius, I. Agartz, H. Petursson,
M. M. Nöthen, M. Rietschel, P. M. Matthews, P. Muglia, L. Peltonen, D. St Clair, D. B. Goldstein,
K. Stefansson, D. A. Collier, Common variants conferring risk of schizophrenia. Nature
460, 744–747 (2009).
24. J. Shi, D. F. Levinson, J. Duan, A. R. Sanders, Y. Zheng, I. Pe’er, F. Dudbridge, P. A. Holmans,
A. S. Whittemore, B. J. Mowry, A. Olincy, F. Amin, C. R. Cloninger, J. M. Silverman, N. G. Buccola,
W. F. Byerley, D. W. Black, R. R. Crowe, J. R. Oksenberg, D. B. Mirel, K. S. Kendler, R. Freedman,
P. V. Gejman, Common variants on chromosome 6p22.1 are associated with schizophrenia.
Nature 460, 753–757 (2009).
25. International Schizophrenia Consortium, S. M. Purcell, N. R. Wray, J. L. Stone, P. M. Visscher,
M. C. O’Donovan, P. F. Sullivan, P. Sklar, Common polygenic variation contributes to risk of
schizophrenia and bipolar disorder. Nature 460, 748–752 (2009).
26. T. Hansen, A. Ingason, S. Djurovic, I. Melle, M. Fenger, O. Gustafsson, K. D. Jakobsen,
H. B. Rasmussen, S. Tosato, M. Rietschel, J. Frank, M. Owen, C. Bonetto, J. Suvisaari,
J. H. Thygesen, H. Pétursson, J. Lönnqvist, E. Sigurdsson, I. Giegling, N. Craddock,
M. C. O’Donovan, M. Ruggeri, S. Cichon, R. A. Ophoff, O. Pietiläinen, L. Peltonen,
M. M. Nöthen, D. Rujescu, D. St Clair, D. A. Collier, O. A. Andreassen, T. Werge, At-risk
variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol. Psychiatry
70, 59–63 (2011).
27. A. Ingason, I. Giegling, S. Cichon, T. Hansen, H. B. Rasmussen, J. Nielsen, G. Jürgens,
P. Muglia, A. M. Hartmann, E. Strengman, C. Vasilescu, T. W. Mühleisen, S. Djurovic,
I. Melle, B. Lerer, H. J. Möller, C. Francks, O. P. Pietiläinen, J. Lonnqvist, J. Suvisaari,
A. Tuulio-Henriksson, M. Walshe, E. Vassos, M. Di Forti, R. Murray, C. Bonetto, S. Tosato;
GROUP Investigators, R. M. Cantor, M. Rietschel, N. Craddock, M. J. Owen, L. Peltonen,
O. A. Andreassen, M. M. Nöthen, D. St Clair, R. A. Ophoff, M. C. O’Donovan, D. A. Collier,
T. Werge, D. Rujescu, A large replication study and meta-analysis in European samples
provides further support for association of AHI1 markers with schizophrenia. Hum. Mol.
Genet. 19, 1379–1386 (2010).
28. D. Rujescu, A. Ingason, S. Cichon, O. P. Pietiläinen, M. R. Barnes, T. Toulopoulou, M. Picchioni,
E. Vassos, U. Ettinger, E. Bramon, R. Murray, M. Ruggeri, S. Tosato, C. Bonetto, S. Steinberg,
E. Sigurdsson, T. Sigmundsson, H. Petursson, A. Gylfason, P. I. Olason, G. Hardarsson,
G. A. Jonsdottir, O. Gustafsson, R. Fossdal, I. Giegling, H. J. Möller, A. M. Hartmann,
P. Hoffmann, C. Crombie, G. Fraser, N. Walker, J. Lonnqvist, J. Suvisaari, A. Tuulio-Henriksson,
S. Djurovic, I. Melle, O. A. Andreassen, T. Hansen, T. Werge, L. A. Kiemeney, B. Franke,
J. Veltman, J. E. Buizer-Voskamp; GROUP Investigators, C. Sabatti, R. A. Ophoff, M. Rietschel,
M. M. Nöthen, K. Stefansson, L. Peltonen, D. St Clair, H. Stefansson, D. A. Collier, Disruption of
the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 18, 988–996 (2009).
29. D. Moreno-De-Luca; SGENE Consortium, J. G. Mulle; Simons Simplex Collection Genetics
Consortium, E. B. Kaminsky, S. J. Sanders; GeneSTAR, S. M. Myers, M. P. Adam, A. T. Pakula,
N. J. Eisenhauer, K. Uhas, L. Weik, L. Guy, M. E. Care, C. F. Morel, C. Boni, B. A. Salbert,
A. Chandrareddy, L. A. Demmer, E. W. Chow, U. Surti, S. Aradhya, D. L. Pickering,
D. M. Golden, W. G. Sanger, E. Aston, A. R. Brothman, T. J. Gliem, E. C. Thorland, T. Ackley,
R. Iyer, S. Huang, J. C. Barber, J. A. Crolla, S. T. Warren, C. L. Martin, D. H. Ledbetter,
Deletion 17q12 is a recurrent copy number variant that confers high risk of autism
and schizophrenia. Am. J. Hum. Genet. 87, 618–630 (2010).
30. H. Stefansson, D. Rujescu, S. Cichon, O. P. Pietiläinen, A. Ingason, S. Steinberg, R. Fossdal,
E. Sigurdsson, T. Sigmundsson, J. E. Buizer-Voskamp, T. Hansen, K. D. Jakobsen, P. Muglia,
C. Francks, P. M. Matthews, A. Gylfason, B. V. Halldorsson, D. Gudbjartsson, T. E. Thorgeirsson,
A. Sigurdsson, A. Jonasdottir, A. Jonasdottir, A. Bjornsson, S. Mattiasdottir, T. Blondal,
M. Haraldsson, B. B. Magnusdottir, I. Giegling, H. J. Möller, A. Hartmann, K. V. Shianna, D. Ge,
A. C. Need, C. Crombie, G. Fraser, N. Walker, J. Lonnqvist, J. Suvisaari, A. Tuulio-Henriksson,
T. Paunio, T. Toulopoulou, E. Bramon, M. Di Forti, R. Murray, M. Ruggeri, E. Vassos, S. Tosato,
M. Walshe, T. Li, C. Vasilescu, T. W. Mühleisen, A. G. Wang, H. Ullum, S. Djurovic, I. Melle,
J. Olesen, L. A. Kiemeney, B. Franke; GROUP, C. Sabatti, N. B. Freimer, J. R. Gulcher,
U. Thorsteinsdottir, A. Kong, O. A. Andreassen, R. A. Ophoff, A. Georgi, M. Rietschel, T. Werge,
H. Petursson, D. B. Goldstein, M. M. Nöthen, L. Peltonen, D. A. Collier, D. St Clair, K. Stefansson,
Large recurrent microdeletions associated with schizophrenia. Nature 455, 232–236 (2008).
31. International Schizophrenia Consortium, Rare chromosomal deletions and duplications in-
crease risk of schizophrenia. Nature 455, 237–241 (2008).
32. S. E. McCarthy, V. Makarov, G. Kirov, A. M. Addington, J. McClellan, S. Yoon, D. O. Perkins,
D. E. Dickel, M. Kusenda, O. Krastoshevsky, V. Krause, R. A. Kumar, D. Grozeva, D. Malhotra,
T. Walsh, E. H. Zackai, P. Kaplan, J. Ganesh, I. D. Krantz, N. B. Spinner, P. Roccanova,
A. Bhandari, K. Pavon, B. Lakshmi, A. Leotta, J. Kendall, Y. H. Lee, V. Vacic, S. Gary,
L. M. Iakoucheva, T. J. Crow, S. L. Christian, J. A. Lieberman, T. S. Stroup, T. Lehtimäki,
K. Puura, C. Haldeman-Englert, J. Pearl, M. Goodell, V. L. Willour, P. Derosse, J. Steele,
L. Kassem, J. Wolff, N. Chitkara, F. J. McMahon, A. K. Malhotra, J. B. Potash, T. G. Schulze,
M. M. Nöthen, S. Cichon, M. Rietschel, E. Leibenluft, V. Kustanovich, C. M. Lajonchere,
J. S. Sutcliffe, D. Skuse, M. Gill, L. Gallagher, N. R. Mendell; Wellcome Trust Case Control
Consortium, N. Craddock, M. J. Owen, M. C. O’Donovan, T. H. Shaikh, E. Susser, L. E. Delisi,
P. F. Sullivan, C. K. Deutsch, J. Rapoport, D. L. Levy, M. C. King, J. Sebat, Microduplications
of 16p11.2 are associated with schizophrenia. Nat. Genet. 41, 1223–1227 (2009).
33. V. Vacic, S. McCarthy, D. Malhotra, F. Murray, H. H. Chou, A. Peoples, V. Makarov, S. Yoon,
A. Bhandari, R. Corominas, L. M. Iakoucheva, O. Krastoshevsky, V. Krause, V. Larach-Walters,
D. K. Welsh, D. Craig, J. R. Kelsoe, E. S. Gershon, S. M. Leal, M. Dell Aquila, D. W. Morris, M. Gill,
A. Corvin, P. A. Insel, J. McClellan, M. C. King, M. Karayiorgou, D. L. Levy, L. E. DeLisi, J. Sebat,
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for
schizophrenia. Nature 471, 499–503 (2011).
34. D. F. Levinson, J. Duan, S. Oh, K. Wang, A. R. Sanders, J. Shi, N. Zhang, B. J. Mowry, A. Olincy,
F. Amin, C. R. Cloninger, J. M. Silverman, N. G. Buccola, W. F. Byerley, D. W. Black, K. S.
Kendler, R. Freedman, F. Dudbridge, I. Pe’er, H. Hakonarson, S. E. Bergen, A. H. Fanous,
P. A. Holmans, P. V. Gejman, Copy number variants in schizophrenia: Confirmation of five
previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am.
J. Psychiatry 168, 302–316 (2011).
35. S. Q. Kuang, D. C. Guo, S. K. Prakash, M. L. McDonald, R. J. Johnson, M. Wang, E. S. Regalado,
L. Russell, J. M. Cao, C. Kwartler, K. Fraivillig, J. S. Coselli, H. J. Safi, A. L. Estrera, S. M. Leal,
S. A. Lemaire, J. W. Belmont, D. M. Milewicz; GenTAC Investigators, Recurrent chromosome
16p13.1 duplications are a risk factor for aortic dissections. PLoS Genet. 7, e1002118 (2011).
36. R. Bachmann-Gagescu, H. C. Mefford, C. Cowan, G. M. Glew, A. V. Hing, S. Wallace,
P. I. Bader, A. Hamati, P. J. Reitnauer, R. Smith, D. W. Stockton, H. Muhle, I. Helbig,
E. E. Eichler, B. C. Ballif, J. Rosenfeld, K. D. Tsuchiya, Recurrent 200-kb deletions of
16p11.2 that include the SH2B1 gene are associated with developmental delay and
obesity. Genet. Med. 12, 641–647 (2010).
37. R. Uher, The role of genetic variation in the causation of mental illness: An evolution-
informed framework. Mol. Psychiatry 14, 1072–1082 (2009).
38. L. Desbonnet, J. L. Waddington, C. M. O’Tuathaigh, Mice mutant for genes associated with
schizophrenia: Common phenotype or distinct endophenotypes? Behav. Brain Res. 204,
39. B. P. Kirby, J. L. Waddington, C. M. O’Tuathaigh, Advancing a functional genomics for
schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene
disruption. Brain Res. Bull. 83, 162–176 (2010).
40. S. J. Clapcote, T. V. Lipina, J. K. Millar, S. Mackie, S. Christie, F. Ogawa, J. P. Lerch, K. Trimble,
M. Uchiyama, Y. Sakuraba, H. Kaneda, T. Shiroishi, M. D. Houslay, R. M. Henkelman,
www.ScienceTranslationalMedicine.org28 September 2011Vol 3 Issue 102 102mr3
on September 28, 2011
J. G. Sled, Y. Gondo, D. J. Porteous, J. C. Roder, Behavioral phenotypes of Disc1 missense Download full-text
mutations in mice. Neuron 54, 387–402 (2007).
41. C. M. O’Tuathaigh, B. P. Kirby, P. M. Moran, J. L. Waddington, Mutant mouse models:
Genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr. Bull.
36, 271–288 (2010).
42. C. M. O’Tuathaigh, D. Babovic, G. J. O’Sullivan, J. J. Clifford, O. Tighe, D. T. Croke, R. Harvey,
J. L. Waddington, Phenotypic characterization of spatial cognition and social behavior in mice
with ‘knockout’ of the schizophrenia risk gene neuregulin 1. Neuroscience 147, 18–27 (2007).
43. C. M. O’Tuathaigh, M. Harte, C. O’Leary, G. J. O’Sullivan, C. Blau, D. Lai, R. P. Harvey, O. Tighe,
A. J. Fagan, C. Kerskens, G. P. Reynolds, J. L. Waddington, Schizophrenia-related endopheno-
types in heterozygous neuregulin-1 ‘knockout’ mice. Eur. J. Neurosci. 31, 349–358 (2010).
44. C. M. O’Tuathaigh, M. Hryniewiecka, A. Behan, O. Tighe, C. Coughlan, L. Desbonnet,
M. Cannon, M. Karayiorgou, J. A. Gogos, D. R. Cotter, J. L. Waddington, Chronic adolescent
exposure to D-9-tetrahydrocannabinol in COMT mutant mice: Impact on psychosis-related
and other phenotypes. Neuropsychopharmacology 35, 2262–2273 (2010).
45. D. H. Blackwood, A. Fordyce, M. T. Walker, D. M. St Clair, D. J. Porteous, W. J. Muir,
Schizophrenia and affective disorders—Cosegregation with a translocation at chromosome
1q42 that directly disrupts brain-expressed genes: Clinical and P300 findings in a family.
Am. J. Hum. Genet. 69, 428–433 (2001).
46. M. Karayiorgou, T. J. Simon, J. A. Gogos, 22q11.2 microdeletions: Linking DNA structural
variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 11, 402–416 (2010).
47. Y. S. Aulchenko, M. V. Struchalin, N. M. Belonogova, T. I. Axenovich, M. N. Weedon, A. Hofman,
A. G. Uitterlinden, M. Kayser, B. A. Oostra, C. M. van Duijn, A. C. Janssens, P. M. Borodin,
Predicting human height by Victorian and genomic methods. Eur. J. Hum. Genet. 17,
48. N. P. Paynter, D. I. Chasman, G. Paré, J. E. Buring, N. R. Cook, J. P. Miletich, P. M. Ridker,
Association between a literature-based genetic risk score and cardiovascular events in
women. JAMA 303, 631–637 (2010).
49. Q. Lu, Y. Song, X. Wang, S. Won, Y. Cui, R. C. Elston, The effect of multiple genetic variants
in predicting the risk of type 2 diabetes. BMC Proc. 3 (Suppl. 7), S49 (2009).
50. S. Ripatti, E. Tikkanen, M. Orho-Melander, A. S. Havulinna, K. Silander, A. Sharma, C. Guiducci,
M. Perola, A. Jula, J. Sinisalo, M. L. Lokki, M. S. Nieminen, O. Melander, V. Salomaa, L. Peltonen,
S. Kathiresan, A multilocus genetic risk score for coronary heart disease: Case-control and
prospective cohort analyses. Lancet 376, 1393–1400 (2010).
51. J. Perälä, J. Suvisaari, S. I. Saarni, K. Kuoppasalmi, E. Isometsä, S. Pirkola, T. Partonen,
A. Tuulio-Henriksson, J. Hintikka, T. Kieseppä, T. Härkänen, S. Koskinen, J. Lönnqvist,
Lifetime prevalence of psychotic and bipolar I disorders in a general population.
Arch. Gen. Psychiatry 64, 19–28 (2007).
52. J. Miettunen, J. Veijola, N. Freimer, D. Lichtermann, L. Peltonen, T. Paunio, M. Isohanni,
M. Joukamaa, J. Ekelund, Data on schizotypy and affective scales are gender and
education dependent—Study in the Northern Finland 1966 Birth Cohort. Psychiatry Res.
178, 408–413 (2010).
53. C. M. O’Tuathaigh, J. L. Waddington, Mutant mouse models: Phenotypic relationships to
domains of psychopathology and pathobiology in schizophrenia. Schizophr. Bull. 36,
54. J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. P. Brunet,
A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty,
P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander, T. R. Golub, The Connectivity Map: Using
gene-expression signatures to connect small molecules, genes, and disease. Science
313, 1929–1935 (2006).
55. T. A. Manolio, F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff, D. J. Hunter, M. I. McCarthy,
E. M. Ramos, L. R. Cardon, A. Chakravarti, J. H. Cho, A. E. Guttmacher, A. Kong, L. Kruglyak,
E. Mardis, C. N. Rotimi, M. Slatkin, D. Valle, A. S. Whittemore, M. Boehnke, A. G. Clark,
E. E. Eichler, G. Gibson, J. L. Haines, T. F. Mackay, S. A. McCarroll, P. M. Visscher, Finding
the missing heritability of complex diseases. Nature 461, 747–753 (2009).
56. C. C. Zygourakis, G. D. Rosen, Quantitative trait loci modulate ventricular size in the mouse
brain. J. Comp. Neurol. 461, 362–369 (2003).
57. M. P. Leussis, M. L. Frayne, M. Saito, E. M. Berry, K. A. Aldinger, G. N. Rockwell, R. P. Hammer Jr.,
A. E. Baskin-Hill, J. B. Singer, J. H. Nadeau, P. Sklar, T. L. Petryshen, Genomic survey of
prepulse inhibition in mouse chromosome substitution strains. Genes Brain Behav. 8,
58. T. L. Petryshen, A. Kirby, R. P. Hammer Jr., S. Purcell, S. B. O’Leary, J. B. Singer, A. E. Hill,
J. H. Nadeau, M. J. Daly, P. Sklar, Two quantitative trait loci for prepulse inhibition of
startle identified on mouse chromosome 16 using chromosome substitution strains.
Genetics 171, 1895–1904 (2005).
59. A. Watanabe, T. Toyota, Y. Owada, T. Hayashi, Y. Iwayama, M. Matsumata, Y. Ishitsuka,
A. Nakaya, M. Maekawa, T. Ohnishi, R. Arai, K. Sakurai, K. Yamada, H. Kondo, K. Hashimoto,
N. Osumi, T. Yoshikawa, Fabp7 maps to a quantitative trait locus for a schizophrenia
endophenotype. PLoS Biol. 5, e297 (2007).
60. K. E. Samocha, J. E. Lim, R. Cheng, G. Sokoloff, A. A. Palmer, Fine mapping of QTL for
prepulse inhibition in LG/J and SM/J mice using F2and advanced intercross lines.
Genes Brain Behav. 9, 759–767 (2010).
61. D. L. Aylor, W. Valdar, W. Foulds-Mathes, R. J. Buus, R. A. Verdugo, R. S. Baric, M. T. Ferris,
J. A. Frelinger, M. Heise, M. B. Frieman, L. E. Gralinski, T. A. Bell, J. D. Didion, K. Hua,
D. L. Nehrenberg, C. L. Powell, J. Steigerwalt, Y. Xie, S. N. Kelada, F. S. Collins, I. V. Yang,
D. A. Schwartz, L. A. Branstetter, E. J. Chesler, D. R. Miller, J. Spence, E. Y. Liu, L. McMillan,
A. Sarkar, J. Wang, W. Wang, Q. Zhang, K. W. Broman, R. Korstanje, C. Durrant, R. Mott,
F. A. Iraqi, D. Pomp, D. Threadgill, F. P. de Villena, G. A. Churchill, Genetic analysis of
complex traits in the emerging Collaborative Cross. Genome Res. 21, 1213–1222
62. G. A. Churchill, D. C. Airey, H. Allayee, J. M. Angel, A. D. Attie, J. Beatty, W. D. Beavis,
J. K. Belknap, B. Bennett, W. Berrettini, A. Bleich, M. Bogue, K. W. Broman, K. J. Buck,
E. Buckler, M. Burmeister, E. J. Chesler, J. M. Cheverud, S. Clapcote, M. N. Cook, R. D. Cox,
J. C. Crabbe, W. E. Crusio, A. Darvasi, C. F. Deschepper, R. W. Doerge, C. R. Farber, J. Forejt,
D. Gaile, S. J. Garlow, H. Geiger, H. Gershenfeld, T. Gordon, J. Gu, W. Gu, G. de Haan,
N. L. Hayes, C. Heller, H. Himmelbauer, R. Hitzemann, K. Hunter, H. C. Hsu, F. A. Iraqi,
B. Ivandic, H. J. Jacob, R. C. Jansen, K. J. Jepsen, D. K. Johnson, T. E. Johnson, G. Kempermann,
C. Kendziorski, M. Kotb, R. F. Kooy, B. Llamas, F. Lammert, J. M. Lassalle, P. R. Lowenstein, L. Lu,
A. Lusis, K. F. Manly, R. Marcucio, D. Matthews, J. F. Medrano, D. R. Miller, G. Mittleman,
B. A. Mock, J. S. Mogil, X. Montagutelli, G. Morahan, D. G. Morris, R. Mott, J. H. Nadeau,
H. Nagase, R. S. Nowakowski, B. F. O’Hara, A. V. Osadchuk, G. P. Page, B. Paigen, K. Paigen,
A. A. Palmer, H. J. Pan, L. Peltonen-Palotie, J. Peirce, D. Pomp, M. Pravenec, D. R. Prows,
Z. Qi, R. H. Reeves, J. Roder, G. D. Rosen, E. E. Schadt, L. C. Schalkwyk, Z. Seltzer,
K. Shimomura, S. Shou, M. J. Sillanpää, L. D. Siracusa, H. W. Snoeck, J. L. Spearow,
K. Svenson, L. M. Tarantino, D. Threadgill, L. A. Toth, W. Valdar, F. P. de Villena, C. Warden,
S. Whatley, R. W. Williams, T. Wiltshire, N. Yi, D. Zhang, M. Zhang, F. Zou; Complex Trait
Consortium, The Collaborative Cross, a community resource for the genetic analysis of
complex traits. Nat. Genet. 36, 1133–1137 (2004).
63. Acknowledgments: The meeting was supported by the SYSGENET network (http://www.
helmholtz-hzi.de/sysgenet/). SYSGENET represents a network of scientists in Europe who
use the mouse as an experimental model system to identify genetic factors that influence
complex phenotypic traits relevant for human diseases. Funding: SYSGENET is funded
through COST, an intergovernmental framework for European Cooperation in Science
and Technology (http://www.cost.eu/about_cost).
Submitted 14 July 2011
Accepted 6 September 2011
Published 28 September 2011
Citation: M. J. Kas, R. S. Kahn, D. A. Collier, J. L. Waddington, J. Ekelund, D. J. Porteous,
K. Schughart, I. Hovatta, Translational neuroscience of schizophrenia: Seeking a meeting of
minds between mouse and man. Sci. Transl. Med. 3, 102mr3 (2011).
www.ScienceTranslationalMedicine.org 28 September 2011Vol 3 Issue 102 102mr3
on September 28, 2011